The only RNA replacement clinical trial to date began in April 2013 as a strategy to deliver miR-34, a tumor-suppressive miRNA that regulates expression of BCL-2 and MYC, to patients with liver-based cancers [108]. The gene discussed is BCL2; the disease is neoplasm.